R&D

Science as our Foundation – for Advancing Technology and Sparking Innovation

Spearheaded by renowned probiotics expert Professor Hsin-Chih Lai, our research has dedicated over 15 years to the research and development of our technology. By integrating advanced research platforms with comprehensive R&D expertise, REVIVEBIO specializes in full-chain development of Next-Generation Probiotics (NGP) and postbiotics.

 

Our approach bridges every stage of innovation—from fundamental scientific discovery to clinical translation—ensuring both precision and efficiency. Through this commitment, REVIVEBIO not only accelerates the application of cutting-edge microbial science but also sparks new possibilities for improving human health and wellbeing.

Our R&D Platforms

With dual R&D bases in Taiwan and Shanghai, we have built a robust multi-faceted validation system:

  • Molecular Biology Research Platform
    Equipped with high-sensitivity molecular detection instruments, mass spectrometry systems and advanced proteomics equipment to profoundly analyze active components and mechanisms of action.
  • Genetic Sequencing Platform
    Established next-generation sequencing (NGS) and whole-genome analysis systems for strain identification, functional prediction and microbiome structural analysis.
  • Cellular Research Platform
    Incorporates immune, neuronal, skin and intestinal epithelial cell models for multi-system functional and safety validation.
  • Application Laboratory
    Equipped for formulation development, stability testing, and small-scale manufacturing, ensuring efficient translation and consistent quality from raw materials to finished products.
  • Preclinical Research Platform
    Designed for nutraceutical and pharmaceutical development, with animal testing facilities and behavioral analysis systems to comprehensively evaluate efficacy in metabolic, immune and neurological disease models.